Market Overview

MetaStat Presents Positive Data Showing Inhibition of the MENA-pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer

Share:

Data presented at the AACR Cancer Dormancy and Residual Disease
meeting support a novel therapeutic approach to combating the spread of
aggressive cancer

MetaStat, Inc. (OTCQB:MTST), a precision medicine company developing
novel anti-metastatic medications for patients with aggressive cancer,
presented positive results from preclinical studies showing treatment
with MAPKAPK2 kinase inhibitors reverse MENA-driven aggressive tumor
cell phenotypes and significantly reduce metastasis at the Cancer
Dormancy and Residual Disease meeting of the American Association for
Cancer Research (AACR) in Montreal, Quebec on June 20, 2018.

"Until recently, the MENA pathway was considered to be an undruggable
target. These results show inhibition of the MENA pathway and reversal
of MENA-dependent phenotypes are possible by targeting MAPKAPK2," stated
Douglas A. Hamilton, MetaStat's President and CEO. "We are leveraging a
proven and highly successful therapeutic strategy in oncology to develop
proprietary first-in-class MAPKAPK2 kinase inhibitors."

MetaStat reported MENA-induced fibronectin remodeling, tumor cell
adhesion and invasion were reversed to MENA-null levels when treated
with MAPKAPK2 inhibitors in vitro. MAPKAPK2 inhibitor monotherapy
reduced lung metastasis similar to the previously published effects of
MENA deficiency in the MMTV-PyMT murine model. Significant decreases in
the number of animals with any detectable circulating tumor cells (CTCs)
following treatment were reported in the MDA-MB-231 human metastatic
triple negative breast cancer model. Further, in contrast to paclitaxel
monotherapy, treatment with the MAPKAPK2 inhibitor alone or in
combination with paclitaxel significantly reduced the growth rate of
MMTV-PyMT primary tumors and the development of lung metastasis.

About MetaStat, Inc.

MetaStat is a precision medicine company dedicated to improving the
survival of patients with aggressive cancer. Our goal is to transform
aggressive cancer into a manageable disease. MetaStat's therapeutic
approach targets the MENA pathway, a critical metastatic pathway
responsible for driving tumor resistance and the spread of aggressive
cancer. Aggressive cancer that spreads or metastasizes to other parts of
the body is responsible for approximately 90% of cancer-related deaths.
MetaStat is developing novel inhibitors targeting the MAPKAPK2 pathway
based on the discovery of its role in the activation of the MENA
pathway. MetaStat is leveraging a proven and highly successful strategy
in oncology through the development of small molecule inhibitors.
MetaStat is located in the Innovation and Design Building in Boston's
Seaport District.

Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the company's Form 10-K and its other filings filed
with the Securities and Exchange Commission. You should consider these
factors in evaluating the forward-looking statements included herein,
and not place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and the
company undertakes no obligation to update such statements.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com